spacer
home > ict > spring 2008 > more than a sleeping partner
PUBLICATIONS
International Clinical Trials

More Than a Sleeping Partner

Martin King of LCG Bioscience outlines some of the most common sleep disorders and their implications, and explains the techniques available for practitioners undertaking specialist sleep trials

Sleep medicine is a fairly new speciality, having been only properly developed within the last 20 years or so. There are currently 89 sleep disorders on the list of International Classification of Sleep Disorders and this is growing all the time (1). The disorders are divided into three groups: dyssomnias, which can be insomnia or hypersomnia (where people sleep too much); parasomnias, which describe undesired events that occur alongside sleep; and medical and psychiatric disorders that affect sleep.

The main area of interest for new sleep drug development by the pharmaceutical industry is the dyssomnia group. It is estimated that 30-35 per cent of the population suffer from some form of insomnia at any time and the economic consequences are dramatic. Insomniacs seem to have more frequent visits to their doctor for other complaints, they probably suffer low mood, and they lose more days from work. So, in terms of the cost to the nation, insomnia is important.

THE MARKET FOR SLEEP MEDICATION

The low number of prescribed hypnotics and the high number of over-the-counter sleep aids indicate that there is the potential for massive growth in sales of new hypnotics. Pharmaceutical companies have produced and, continue to develop, hypnotics and treatments for insomnia, and alerting medications to combat sleepiness, particularly daytime sleepiness.

However, there are different types of insomnia. Take, for example, transient insomnia. We are all aware that anxiety can bring on insomnia – perhaps if you are worried about the events of the next day. Or you may have insomnia because you’ve drunk too much coffee.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Martin King began his career in sleep medicine around 20 years ago, and has worked in the NHS and the private sector, and has spent a brief period in the US. He is a member of the World Association of Sleep Medicine, the European Sleep Research Society, American Academy of Sleep Medicine and the British Sleep Society. Martin was Manager of the UK’s largest clinical sleep laboratory and he has assessed thousands of patients across the spectrum of sleep disorders. He has authored papers in a number of peer reviewed journals and is regularly asked to contribute to teaching programmes. Martin recently joined LCG Bioscience in Cambridge, UK, to head the new sleep facility which is designed to deliver both early and late phase clinical trials
spacer
Martin King
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo received the Customer Satisfaction Management Certificate (ISO 10002).

Turkish Cargo, the fastest growing air cargo brand in the world, obtained the "Customer Satisfaction Management Certificate" (ISO 10002) and developed the Cargo Customers Feedback Management Policy accordingly.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement